ClearPoint Neuro Reports Third Quarter 2026 Results

SOLANA BEACH, CA / ACCESS Newswire / October 28, 2026 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced financial results for its third quarter ended September 30, 2026.

Third Quarter 2026 Highlights * Reported third quarter revenue of $12.1 million, representing 36% overall growth, including the recently acquired IRRAflow Portfolio; * Neurosurgery navigation and therapy, which includes navigation, laser, drill and IRRAflow products, increased 59% to $5.4 million in the quarter; * Achieved record capital equipment and software revenue of $1.7 million, representing 68% growth in the quarter, including the recently acquired IRRAflow equipment; * Increased biologics and drug delivery revenue to $4.9 million, an 11% year-over-year increase; * First formal BLA was submitted by one partner for the treatment of Huntington's Disease; * ClearPoint is an industry partner in a five-year, $2.98 million competitively awarded NCI R01, led by Dartmouth Health to advance MR-guided laser therapy for spinal metastases.¹ The program runs from benchtop through large subject validation to a clinical trial, using the ClearPoint Prism system. ClearPoint contributes technical, software development, and procedural expertise. This is early-stage research that supports our spine LITT roadmap; * Received net proceeds of $22.0 million from the at-the-market equity offering program; and * Reported cash and cash equivalents of $46.2 million as of September 30, 2026. "Throughout 2026 we have continued to make substantial strategic progress in building our comprehensive drug delivery ecosystem, adding new biopharma partners, and assisting existing partners progress through the regulatory process globally," commented Joe Burnett, President and CEO at ClearPoint Neuro. "The acceleration of our financial performance in the third quarter was driven by our core organic clinical product revenue, as well as our biologics and drug delivery revenue both returning to double-digit growth. The 36% revenue growth outpaced operating expense growth of 23% in the third quarter, as the completion of the IRRAflow product integration has enabled improved operating leverage. Our current cash balance of $46.2 million provides us with additional confidence to fund our product pipeline which now includes AI Derived Planning and Simulation, Neuro Navigation in the MRI and Operating Room, Laser Therapy and Access, IRRAflow CSF management, Robotic Surgery, Focused Ultrasound, as well as our comprehensive drug delivery ecosystem including pre-clinical and clinical services. This unmatched portfolio and partnership advantage will make us the premier therapy enabling company in the cranial neurosurgery space for many years to come."